Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cell & Gene Therapy
Biotech
Gamida accepts sale to investment firm to survive
With no luck finding a partner for Omisirge, Gamida has accepted the only way to survive is for its principal lender to acquire the company.
James Waldron
Mar 27, 2024 9:53am
Nanoscope eyes market after phase 2b retinal disease data drop
Mar 26, 2024 7:00am
Intellia opts out of hemophilia gene editing work with Regeneron
Mar 22, 2024 11:21am
Nkarta's blood cancer CAR stalls again, driving deprioritization
Mar 22, 2024 9:11am
Tenaya's cardiac gene therapy boosts long-term survival in mice
Mar 18, 2024 2:33pm
Astellas puts the cork back in $350M Xork deal with Cartesian
Mar 14, 2024 10:41am
More News
CAR-T for brain cancer extends survival in phase 1 trial
Mar 12, 2024 9:00am
VC investment in biopharma dropped nearly $7B in 2023: PitchBook
Mar 5, 2024 5:00am
BioCardia rejigs phase 3 heart failure data to find a path
Mar 4, 2024 10:15am
FDA lifts hold on Iovance's lung cancer cell therapy trial
Mar 4, 2024 9:44am
See more stories